Ilyang Pharmaceutical Co.,Ltd (007570.KS)
KRW 10880.0
(-2.07%)
KRW 10880.0
(-2.07%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 75.67 Billion KRW | 189.74% |
| 2022 | 26.11 Billion KRW | -51.94% |
| 2021 | 54.35 Billion KRW | -11.91% |
| 2020 | 61.69 Billion KRW | -33.42% |
| 2019 | 92.67 Billion KRW | -23.88% |
| 2018 | 121.74 Billion KRW | -6.93% |
| 2017 | 130.81 Billion KRW | -7.71% |
| 2016 | 141.73 Billion KRW | -8.37% |
| 2015 | 154.67 Billion KRW | -12.35% |
| 2014 | 176.47 Billion KRW | 4.57% |
| 2013 | 168.76 Billion KRW | 17.13% |
| 2012 | 144.07 Billion KRW | 9.04% |
| 2011 | 132.13 Billion KRW | 5.62% |
| 2010 | 125.1 Billion KRW | 21.17% |
| 2009 | 103.24 Billion KRW | 32.36% |
| 2008 | 78 Billion KRW | 42.51% |
| 2007 | 54.73 Billion KRW | 29.43% |
| 2006 | 42.29 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 85.65 Billion KRW | 10.85% |
| 2024 Q1 | 77.26 Billion KRW | 2.11% |
| 2023 FY | 75.67 Billion KRW | 189.74% |
| 2023 Q4 | 75.67 Billion KRW | -9.18% |
| 2023 Q3 | 83.32 Billion KRW | -3.31% |
| 2023 Q2 | 86.17 Billion KRW | 5.47% |
| 2023 Q1 | 81.7 Billion KRW | 212.83% |
| 2022 Q4 | 26.11 Billion KRW | -17.73% |
| 2022 Q3 | 31.74 Billion KRW | -4.2% |
| 2022 FY | 26.11 Billion KRW | -51.94% |
| 2022 Q1 | 34.7 Billion KRW | -36.15% |
| 2022 Q2 | 33.13 Billion KRW | -4.5% |
| 2021 Q4 | 54.35 Billion KRW | 10.31% |
| 2021 Q1 | 68.96 Billion KRW | 11.77% |
| 2021 Q2 | 65.84 Billion KRW | -4.52% |
| 2021 Q3 | 49.27 Billion KRW | -25.17% |
| 2021 FY | 54.35 Billion KRW | -11.91% |
| 2020 Q4 | 61.69 Billion KRW | -29.53% |
| 2020 Q1 | 95.26 Billion KRW | 2.79% |
| 2020 Q3 | 87.55 Billion KRW | -10.6% |
| 2020 FY | 61.69 Billion KRW | -33.42% |
| 2020 Q2 | 97.92 Billion KRW | 2.8% |
| 2019 Q2 | 114.72 Billion KRW | 1.47% |
| 2019 FY | 92.67 Billion KRW | -23.88% |
| 2019 Q4 | 92.67 Billion KRW | -20.8% |
| 2019 Q3 | 117 Billion KRW | 1.99% |
| 2019 Q1 | 113.06 Billion KRW | -7.14% |
| 2018 Q3 | 127.03 Billion KRW | -1.61% |
| 2018 Q4 | 121.74 Billion KRW | -4.16% |
| 2018 FY | 121.74 Billion KRW | -6.93% |
| 2018 Q1 | 123.03 Billion KRW | -5.94% |
| 2018 Q2 | 129.11 Billion KRW | 4.94% |
| 2017 FY | 130.81 Billion KRW | -7.71% |
| 2017 Q3 | 146.68 Billion KRW | 3.4% |
| 2017 Q2 | 141.86 Billion KRW | -0.9% |
| 2017 Q1 | 143.15 Billion KRW | 1.01% |
| 2017 Q4 | 130.81 Billion KRW | -10.82% |
| 2016 Q1 | 124.73 Billion KRW | 0.0% |
| 2016 Q3 | 154.41 Billion KRW | -0.34% |
| 2016 Q2 | 154.93 Billion KRW | 24.21% |
| 2016 FY | 141.73 Billion KRW | -8.37% |
| 2016 Q4 | 141.73 Billion KRW | -8.21% |
| 2015 FY | 154.67 Billion KRW | -12.35% |
| 2015 Q3 | 115.01 Billion KRW | -28.92% |
| 2015 Q2 | 161.8 Billion KRW | -8.31% |
| 2015 Q1 | 176.47 Billion KRW | 62.36% |
| 2014 FY | 176.47 Billion KRW | 4.57% |
| 2014 Q2 | 153.75 Billion KRW | -8.89% |
| 2014 Q4 | 108.69 Billion KRW | -42.2% |
| 2014 Q3 | 188.05 Billion KRW | 22.31% |
| 2014 Q1 | 168.76 Billion KRW | 0.0% |
| 2013 FY | 168.76 Billion KRW | 17.13% |
| 2013 Q1 | 144.07 Billion KRW | -3.37% |
| 2012 Q4 | 149.1 Billion KRW | 84.45% |
| 2012 Q3 | 80.83 Billion KRW | 5.65% |
| 2012 Q1 | 132.13 Billion KRW | 2.85% |
| 2012 FY | 144.07 Billion KRW | 9.04% |
| 2012 Q2 | 76.51 Billion KRW | -42.09% |
| 2011 Q2 | 76.42 Billion KRW | -38.91% |
| 2011 FY | 132.13 Billion KRW | 5.62% |
| 2011 Q1 | 125.1 Billion KRW | 1.42% |
| 2011 Q3 | 128.34 Billion KRW | 67.94% |
| 2011 Q4 | 128.47 Billion KRW | 0.09% |
| 2010 Q3 | 114.12 Billion KRW | 7.1% |
| 2010 Q4 | 123.34 Billion KRW | 8.08% |
| 2010 Q2 | 106.56 Billion KRW | 0.0% |
| 2010 FY | 125.1 Billion KRW | 21.17% |
| 2009 Q1 | 78 Billion KRW | -5.15% |
| 2009 FY | 103.24 Billion KRW | 32.36% |
| 2009 Q4 | 96.42 Billion KRW | 14.18% |
| 2009 Q3 | 84.44 Billion KRW | 6.43% |
| 2009 Q2 | 79.34 Billion KRW | 1.72% |
| 2008 Q2 | 65.52 Billion KRW | 19.71% |
| 2008 Q1 | 54.73 Billion KRW | 10.49% |
| 2008 Q4 | 82.24 Billion KRW | 10.6% |
| 2008 Q3 | 74.35 Billion KRW | 13.48% |
| 2008 FY | 78 Billion KRW | 42.51% |
| 2007 Q3 | 43.16 Billion KRW | -33.67% |
| 2007 FY | 54.73 Billion KRW | 29.43% |
| 2007 Q4 | 49.54 Billion KRW | 14.79% |
| 2007 Q2 | 65.06 Billion KRW | 0.0% |
| 2006 FY | 42.29 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -759.72% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 86.771% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 75.657% |
| HANDOK Inc. | 283.45 Billion KRW | 73.303% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -277.013% |
| Yuhan Corporation | -69.18 Billion KRW | 209.378% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 60.982% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 2153.134% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 85.388% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 333.334% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -105.429% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 8.296% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -201.392% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -759.72% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 147.342% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 62.341% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 55.731% |
| JW Holdings Corporation | 480.68 Billion KRW | 84.257% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 54.02% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -64286.788% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 50.979% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -3118.395% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -229.0% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 56.751% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -45.599% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -759.72% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 52.194% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 78.872% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 50.979% |
| Yuhan Corporation | -69.18 Billion KRW | 209.378% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 44.353% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -26.813% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 82.366% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 50.979% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 34.896% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -360.726% |
| CKD Bio Corp. | 143.29 Billion KRW | 47.19% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 34.801% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 414.503% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 269.166% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -3118.395% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 82.103% |
| Boryung Corporation | 187.72 Billion KRW | 59.689% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 205.338% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 0.0% |
| JW Lifescience Corporation | 26.09 Billion KRW | -190.045% |